Company: EDSA
Filing Date: 2025-02-14
Form Type: 10-Q
Source: 0001171843-25-000866
Chunk: 10

Company: Edesa Biotech, Inc.
Filing Date: 2025-02-14
Form: 10-Q
Item: Part I, Item 8
Chunk 10
---
 is 642,737. The remaining number of shares available to grant at December 31, 2024 is 119,574.

The Company’s 2019 Plan allows options to be granted to directors, officers, employees and certain external consultants and advisers. Under the 2019 Plan, the option term is not to exceed 10 years and the exercise price of each option is determined by the independent members of the Board of Directors.

12

Options have been granted under the 2019 Plan allowing the holders to purchase common shares of the Company as follows:

			Number of Options (#)

			Weighted Average Exercise Price

			Weighted Average Grant Date Fair Value

			Three Months Ended December 31, 2024

			Balance - September 30, 2024

			383,040

			$
			24.93

			$
			18.33

			Balance - December 31, 2024

			383,040

			$
			24.93

			$
			18.33

			Three Months Ended December 31, 2023

			Balance - September 30, 2023

			420,615

			$
			25.60

			$
			18.84

			Granted

			500

			4.10

			3.10

			Expired

			(106
			)

			960.00

			960

			Balance - December 31, 2023

			421,009

			$
			25.46

			$
			18.67

During the three months ended December 31 2024, there were no employee or director options granted. During the three months ended December 31, 2023, there were 500 employee options granted and no director options granted. The options have a term of 10 years and an exercise price equal to the Nasdaq closing price on the grant date.

The weighted average contractual life remaining on the outstanding options at December 31, 2024 is 77 months.

The following table summarizes information about the options under the 2019 Plan outstanding and exercisable at December 31, 2024:

			Number of Options (#) 

			Exercisable at
			December 31, 2024 (#) 

			Range of Exercise Prices 

			Expiry Dates